FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Zafirlukast Oral Tablets
Status: Discontinuation
»Therapeutic Categories: Pulmonary/Allergy

Expand all

Par Pharmaceutical (New 03/17/2022)

Company Contact Information:
800-828-9393

Presentation Posting Date Related Information
Zafirlukast 10 mg Tablets, (NDC 49884-549-02) 03/17/2022
Zafirlukast 20 mg Tablets, (NDC 49884-554-02) 03/17/2022
Accolate® Zafirlukast 10 mg Tablets, (NDC 49884-589-02) 03/17/2022
Accolate® Zafirlukast 20 mg Tablets, (NDC 49884-590-02) 03/17/2022

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English